RingConn Smart Ring review: keeping things simple
RingConns Smart Ring is a lightweight, durable wearable that does the basics right
Source: t3.com
📰 Activity Score News
Activity Score News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Activity Score. Real-time updates on events, politics, business and more.
Oura vs. RingConn: Features, price and key differences compared
Looking to choose between Oura and RingConn's smart rings? This guide compares all the key differences and similarities.
Source: wareable.com
Oura Ring Generation 3 Review: One Editor's Honest Experience
Eyeing the Oura Ring Generation 3? I tested the smart ring’s sleep, fitness, stress, and cycle tracking for a month—heres what you need to know before buying.
Source: cosmopolitan.com
The Average Snapchat Score Is 16 000
It’s no secret that Snapchat is one of the most popular social media platforms out there. And, with over 300 million daily active users, it’s also one of the most used. But what about Snapchat scores? Do most people have a high Snapchat score? Well, according to a recent study, the answer is yes. In […]
Source: hapblog.com
Still No Easy Way to Take RA Patients Off Anti-TNF Drugs
Randomized trial tests a withdrawal strategy, with mixed results
Source: medpagetoday.com
Pegozafermin Improves Fibrosis in NASH in Phase 2b Study
In the phase 2b ENLIVEN trial, the investigational drug pegozafermin met both primary endpoints at 24 weeks and led to improvements in fibrosis, paving the way for phase 3 development.
United States San Diego University Of Chicago Michael Charlton Rohit Loomba International Liver Congress
Source: medscape.com
Viridian Announces Positive Data from Ongoing Phase 1/2
- Significant and rapid improvement in both signs and symptoms of TED after two infusions of 3 mg/kg, generally consistent with prior 10 and 20 mg/kg...
Source: globenewswire.com
Efruxifermin Led to NASH Resolution, Fibrosis Improvement in Mid-Stage Trial
Both 50- and 28-mg doses improved fibrosis vs placebo, without worsening of NASH
Source: medpagetoday.com
Viridian Presents Positive Clinical Data from Ongoing VRDN-001 Phase 1/2 Trial in Active Thyroid Eye Disease (TED) Patients During Late-Breaking Presentations at the American Thyroid Association (ATA) 91st Annual Meeting - Viridian Therapeutics (NASDAQ:VRDN) - Press Release
- Clinical and in vitro data presented in three late-breaking presentations at ATA provide emerging evidence of VRDN-001 efficacy and differentiation
Source: wiredprnews.com
Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
/PRNewswire/ -- Regeneron Pharmaceuticals (Nasdaq: REGN) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today preliminary Phase 1 data supporting...
Source: prnewswire.com